A share price of Candel Therapeutics Inc [CADL] is currently trading at $5.02, up 13.57%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CADL shares have gain 12.30% over the last week, with a monthly amount drifted -3.83%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Candel Therapeutics Inc [NASDAQ: CADL] stock has seen the most recent analyst activity on October 28, 2025, when Stephens initiated its Overweight rating and assigned the stock a price target of $15. Previously, BofA Securities downgraded its rating to Neutral on September 03, 2025, and kept the price target unchanged to $7. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $25 on February 20, 2025. Canaccord Genuity initiated its recommendation with a Buy and recommended $20 as its price target on February 19, 2025. BofA Securities started tracking with a Buy rating for this stock on February 07, 2025, and assigned it a price target of $15. In a note dated December 02, 2022, H.C. Wainwright initiated an Buy rating and provided a target price of $11 on this stock.
Candel Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $4.25 and $14.60. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. Candel Therapeutics Inc [NASDAQ: CADL] shares were valued at $5.02 at the most recent close of the market. An investor can expect a potential return of 198.8% based on the average CADL price forecast.
Analyzing the CADL fundamentals
Gross Profit Margin for this corporation currently stands at -0.73% with Operating Profit Margin at -40.66%, Pretax Profit Margin comes in at -11.49%, and Net Profit Margin reading is -11.49%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.15 and Total Capital is -0.49. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.61 points at the first support level, and at 4.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.24, and for the 2nd resistance point, it is at 5.46.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Candel Therapeutics Inc [NASDAQ:CADL] is 8.25. In addition, the Quick Ratio stands at 8.25 and the Cash Ratio stands at 7.96.
Transactions by insiders
Recent insider trading involved Nichols William Garrett, Chief Medical Officer, that happened on Jul 28 ’25 when 937.0 shares were sold. Chief Medical Officer, Nichols William Garrett completed a deal on Jun 30 ’25 to sell 781.0 shares. Meanwhile, Officer WILLIAM GARRETT NICHOLS bought 3593.0 shares on Jun 30 ’25.
